J.P. Morgan analyst James Gordon maintained a Hold rating on Takeda Pharmaceutical Company (NYSE:TAK) on Tuesday, setting a price target of $15, which is approximately 8.62% above the present share price of $13.81.
Gordon expects Takeda Pharmaceutical Company to post earnings per share (EPS) of $29.24 for the fourth quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Hold rating of shares in Takeda Pharmaceutical Company, with an average price target of $16.3.
The analysts price targets range from a high of $17.6 to a low of $15.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $844.82 billion and a net profit of $97.43 billion. The company's market cap is $43.44 billion.
According to TipRanks.com, J.P. Morgan analyst James Gordon is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 0.8% and a 53.13% success rate.
Takeda Pharmaceutical Company Limited is engaged in the research and development, manufacturing, marketing, and importing and exporting of pharmaceutical drugs and other healthcare products. The company offers pharmaceutical products in the areas of oncology, neuroscience, gastroenterology, and rare diseases.